+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Tumor Treating Fields TTFields given with pembrolizumab and platinum-based chemotherapy in patients with advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. This study, called LUNAR-2, compares this combination to pembrolizumab and chemotherapy alone, focusing on overall survival and progression-free survival. It also examines outcomes based on the specific subtype of lung cancer and PD-L1 expression levels. Participants receive either the combination of TTFields delivered by the portable NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy, or pembrolizumab and chemotherapy without TTFields. The NovoTTF-200T device delivers electric fields to disrupt cancer cell division and is used continuously at home. Treatments are given according to a randomized, open-label design. During the study, participants will be monitored regularly with evaluations of survival and disease progression for up to six years. Researchers will track response rates, duration of response, disease control, and adverse events. Assessments include measuring cancer status by standardized criteria. This long-term follow-up helps understand the effects and safety of the treatments over time.

Age: 18Years +All GendersPhase 3
104 locations